CytoDyn will webcast on March 22nd to provide an update on COVID-19 initiatives and expected … | provide

VANCOUVER, Wash., March 17, 2021 (GLOBE NEWSWIRE) – CytoDyn Inc. (OTC.QB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing Vyrologix ™ (leronlimab-PRO 140)) , a CCR5 antagonist with potential for multiple therapeutic indications, announced today that Dr. Nader Pourhassan, President and Chief Executive Officer, Dr. Scott Kelly, Chairman and Chief Medical Officer, Dr. Christopher Recknor, Chief Operating Officer and Mahboob Rahman, MD, Ph.D., Chief Scientific Officer, will webcast the investment community on Monday, March 22, 2021.

Management will inform shareholders about the company’s recent COVID-19-related filings for the conditional EUA with the FDA in the US, the provisional injunction in Canada and the accelerated ongoing review in the UK, as well as possible similar filings in Brazil and the Philippines keep up to date. Management will also provide updates on its active studies on COVID-19, NASH and cancer, as well as the expected deadlines for filing BLA HIV infections in the US, Canada and the UK

Management will have approximately 60 minutes to answer questions posed online by analysts and investors.

Date: Monday, March 22, 2021 Time: 1:00 p.m. PT / 4:00 p.m. ET Dial-in: None. Ask:

Questions can be submitted online prior to the webcast to

Questions can be submitted during the webcast using the webcast link below.

This is a “listen only” webcast, accessible from the CytoDyn corporate website at www.cytodyn.com under the Investors / IR Calendar section and archived for 30 days. Attendees are encouraged to go to the website 15 minutes before the webcast begins to register, download, and install the required software. Please note that the website below is only operational approx. 60 minutes before the start of the webcast, which you can access via the following link:

The replay will be available approximately 60 minutes after the webcast closes and can be accessed through the link above until April 22, 2021.

Copyright 2021 GlobeNewswire, Inc.